These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 34516023)
1. Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial. Wirth LJ; Robinson B; Boni V; Tan DSW; McCoach C; Massarelli E; Hess LM; Jen MH; Kherani J; Olek E; Subbiah V Oncologist; 2022 Feb; 27(1):13-21. PubMed ID: 34516023 [TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes with selpercatinib treatment in patients with RET-driven cancers in the phase I/II LIBRETTO-001 trial. Raez LE; Kang H; Ohe Y; Khanal M; Han Y; Szymczak S; Barker SS; Gilligan AM ESMO Open; 2024 May; 9(5):103444. PubMed ID: 38749381 [TBL] [Abstract][Full Text] [Related]
3. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032 [TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced Lu S; Zheng X; Sun Y; Huang D; Wu L; Ji Q; Zhou C; Zhou J; Guo Y; Ge M; Ding D; Shao J; Zhang W; Gao M; Cheng Y Ther Adv Med Oncol; 2023; 15():17588359231189429. PubMed ID: 37655205 [TBL] [Abstract][Full Text] [Related]
5. Durability of Response With Selpercatinib in Patients With Wirth LJ; Brose MS; Subbiah V; Worden F; Solomon B; Robinson B; Hadoux J; Tomasini P; Weiler D; Deschler-Baier B; Tan DSW; Maeda P; Lin Y; Singh R; Bayt T; Drilon A; Cassier PA J Clin Oncol; 2024 Sep; 42(27):3187-3195. PubMed ID: 39094065 [No Abstract] [Full Text] [Related]
6. Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial. Minchom A; Tan AC; Massarelli E; Subbiah V; Boni V; Robinson B; Wirth LJ; Hess LM; Jen MH; Kherani J; Olek E; McCoach CE Oncologist; 2022 Feb; 27(1):22-29. PubMed ID: 34523767 [TBL] [Abstract][Full Text] [Related]
7. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200 [No Abstract] [Full Text] [Related]
8. Efficacy of Selpercatinib in Wirth LJ; Sherman E; Robinson B; Solomon B; Kang H; Lorch J; Worden F; Brose M; Patel J; Leboulleux S; Godbert Y; Barlesi F; Morris JC; Owonikoko TK; Tan DSW; Gautschi O; Weiss J; de la Fouchardière C; Burkard ME; Laskin J; Taylor MH; Kroiss M; Medioni J; Goldman JW; Bauer TM; Levy B; Zhu VW; Lakhani N; Moreno V; Ebata K; Nguyen M; Heirich D; Zhu EY; Huang X; Yang L; Kherani J; Rothenberg SM; Drilon A; Subbiah V; Shah MH; Cabanillas ME N Engl J Med; 2020 Aug; 383(9):825-835. PubMed ID: 32846061 [TBL] [Abstract][Full Text] [Related]
9. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Jozaghi Y; Zafereo M; Williams MD; Gule-Monroe MK; Wang J; Grubbs EG; Vaporciyan A; Hu MI; Busaidy N; Dadu R; Waguespack SG; Subbiah V; Cabanillas M Head Neck; 2021 Jan; 43(1):E7-E12. PubMed ID: 33169506 [TBL] [Abstract][Full Text] [Related]
11. Fluctuating obliterative bronchiolitis in RET-mutant medullary thyroid cancer patient treated with selpercatinib. Gambale C; Prete A; Romei C; Celi A; Elisei R; Matrone A Eur Thyroid J; 2024 Oct; 13(5):. PubMed ID: 39136571 [TBL] [Abstract][Full Text] [Related]
12. Phase 3 Trial of Selpercatinib in Advanced Hadoux J; Elisei R; Brose MS; Hoff AO; Robinson BG; Gao M; Jarzab B; Isaev P; Kopeckova K; Wadsley J; Führer D; Keam B; Bardet S; Sherman EJ; Tahara M; Hu MI; Singh R; Lin Y; Soldatenkova V; Wright J; Lin B; Maeda P; Capdevila J; Wirth LJ; N Engl J Med; 2023 Nov; 389(20):1851-1861. PubMed ID: 37870969 [TBL] [Abstract][Full Text] [Related]
13. Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives. Zhang Y; Zheng WH; Zhou SH; Gu JL; Yu Q; Zhu YZ; Yan YJ; Zhu Z; Shang JB Cell Commun Signal; 2024 Sep; 22(1):460. PubMed ID: 39342195 [TBL] [Abstract][Full Text] [Related]
14. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198 [TBL] [Abstract][Full Text] [Related]
15. Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib. Elisei R; Ciampi R; Matrone A; Prete A; Gambale C; Ramone T; Simeakis G; Materazzi G; Torregrossa L; Ugolini C; Romei C J Clin Endocrinol Metab; 2022 Jul; 107(8):2195-2202. PubMed ID: 35616103 [TBL] [Abstract][Full Text] [Related]
16. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment. Dabelić N; Jukić T; Fröbe A Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884 [TBL] [Abstract][Full Text] [Related]
17. Management of Advanced Medullary Thyroid Carcinoma: Current Systemic Therapy Options. Jara MA Crit Rev Oncog; 2024; 29(3):83-90. PubMed ID: 38683155 [TBL] [Abstract][Full Text] [Related]
18. Primary resistance to selpercatinib in a patient with advanced medullary thyroid cancer. Pitoia F; Trimboli P; Abelleira E Endocrine; 2024 Oct; 86(1):109-113. PubMed ID: 38801596 [TBL] [Abstract][Full Text] [Related]
19. State of the art and future directions in the systemic treatment of medullary thyroid cancer. Jager EC; Broekman KE; Kruijff S; Links TP Curr Opin Oncol; 2022 Jan; 34(1):1-8. PubMed ID: 34669647 [TBL] [Abstract][Full Text] [Related]
20. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]